Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials

The recent development of monoclonal antibodies targeted to proprotein convertase subtilisin/kexin type 9 (PCSK9), e.g., PCSK9 inhibitors has revolutionized the landscape of lipid management. Many clinical trials assessing this class have demonstrated remarkable and consistent reductions in low-dens...

Full description

Bibliographic Details
Main Authors: Nathan D. Wong, Michael D. Shapiro
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
proprotein convertase sibtilisin / kexin type 9 (PCSK9)
dyslipidemia
low density lipoprotein-cholesterol (LDL-C)
cardiovascular disease
prevention
clinical trials
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2019.00014/full

Similar Items

Similar Items